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Cardiac Damage Induced by Renal Ischemia/Reperfusion 
Injury in Hyperlipidemic Rats: Role of PPAR-a Agonist
Yagnik Bhalodia,1 Navin Sheth,2 Jitendra Vaghasiya,1 Nurudin Jivani1
Background: In view of the reported efficacy of peroxisome proliferator-activated receptor-α in renal ischemia/
reperfusion (I/R) injury, the present study was designed to investigate the effect of fenofibrate on cardiac dam-
age induced by renal I/R in hyperlipidemic rats.
Methods: Male Wistar rats were divided into five groups: Group 1, normal control; Group 2, hyperlipidemic 
control; Group 3, renal I/R injury; Group 4, hyperlipidemic + renal I/R injury; and Group 5, hyperlipidemic + renal 
I/R injury + fenofibrate. Hyperlipidemia was induced by feeding the rats with cholesterol (500 mg/kg per oral) 
in hydrogenated ground nut oil (as a vehicle) for 4 weeks. At the end of the fourth week, renal I/R injury was 
induced by occlusion of both renal vascular pedicles for 60 minutes, followed by 24-hour reperfusion. In the 
treatment group, fenofibrate (100 mg/kg per oral, dissolved in water containing 0.2% methyl cellulose) was given 
2 weeks before I/R injury. At the end of the experiment, blood and heart were isolated for biochemical analysis.
Results: Hyperlipidemic I/R rats have significantly higher levels of cardiac lipid peroxidation, xanthine oxidase, 
nitric oxide and myeloperoxidase, and lower levels of antioxidant enzymes (reduced glutathione, superoxide 
dismutase and catalase) compared to non-hyperlipidemic I/R rats, the levels of which were restored after treat-
ment with fenofibrate. Cardiac functional enzymes were normalized after the administration of fenofibrate.
Conclusion: This study elucidated the oxidative role of cardiac damage induced by renal I/R via inflammatory 
mediators, which was attenuated by fenofibrate. [Hong Kong J Nephrol 2009;11(2):59–65]
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INTRODUCTION
Cardiovascular disorders such as hypertension and 
atherosclerosis are becoming more and more common, 
and their prevalence is even higher in affluent societies 
[1]. Because of the important role of the kidneys in 
maintaining homeostasis, kidney disease can affect 
almost every body system [2]. Chronic kidney disease 
is a major cause and a consequence of cardiovascular 
disease. Hyperlipidemia is a major risk factor for car-
diovascular complications, and may ultimately lead to 
ischemic nephropathy, with patients requiring renal 
transplantation in later life [3,4]. Renal ischemia/reper-
fusion (I/R) injury is a serious complication of this 
procedure. In hyperlipidemic rats, it was demonstrated 
that a comparatively short ischemia time of 30 minutes 
resulted in reversible acute renal failure compared to in 
non-hyperlipidemic rats, and causes progressive injury 
with end-stage renal failure [5]. Renal I/R may cause 
distant organ damage such as cardiac damage [6]. It is 
believed that I/R injury induces an inflammatory re-
sponse that elicits tissue damage in a number of organs. 
Reactive oxygen species (ROS) with nitric oxide (NO) 
play a key role in the pathophysiology of renal I/R injury 
[7,8]. It has been demonstrated that renal I/R injury may 
cause myocardial oxidative stress and increase cardiac 
lipid peroxidation [6].
Peroxisome proliferator-activated receptor-α 
(PPAR-α) is a nuclear receptor that is involved in the 
regulation of energy substrate metabolism and inflam-
matory responses. Millions of patients use the PPAR-α 
activator fenofibrate for the treatment of hyperlipidemia. 
PPAR-α expression is prominent in tissues like the 
kidneys and heart [9,10]. It was shown previously that 
PPAR-α ligands protect the rat kidney against renal I/R 
injury [10,11], but the function of PPAR-α in the heart 
remains uncertain. In particular, it is unknown whether 
activation of PPAR-α modifies cardiac responses in-
duced by renal I/R injury. Thus, the present study was 
designed to investigate the protective effects of fenofibrate 
on remote cardiac damage induced by renal I/R injury 
in hyperlipidemic rats.
MATERIALS AND METHODS
Animals and experimental procedures
Male Wistar rats weighing 180–200 g were placed in a 
quiet room where the temperature was 21 ± 2°C and 
humidity was 60 ± 5%, and where a 12-hour light–12-
hour dark cycle was maintained. All the experiments in 
this study were performed in accordance with the CPC-
SEA (Committee for the Purpose of Control and Super-
vision on Experiments on Animals) Guidelines, and 
were approved by our institution’s animal ethics com-
mittee on animal research.
The rats were randomly divided into five groups. 
Group 1 (n = 6): normal control (NC); Group 2 (n = 6): 
hyperlipidemic control (HC); Group 3 (n = 6): renal 
I/R injury (I/R); Group 4 (n = 6): hyperlipidemic + 
renal I/R injury (HC + I/R); and Group 5 (n = 6): 
hyperlipidemic + renal I/R injury + fenofibrate 
(HC + I/R + FF).
Hyperlipidemia was induced by feeding the rats with 
cholesterol (Sigma Chemical Co., St Louis, MO, USA) 
in hydrogenated ground nut oil (as a vehicle), which 
was given orally at a dose of 500 mg/kg for 4 weeks 
[12]. Control animals were fed with the vehicle alone. 
Development of hyperlipidemia was confirmed by 
measuring blood cholesterol levels weekly during cho-
lesterol feeding. At the end of the second week, the rats 
were hyperlipidemic.
Starting on the same day of the diagnosis of hyper-
lipidemia, fenofibrate 100 mg/kg (dissolved in water 
containing 0.2% methyl cellulose) was given orally for 
2 weeks. At the end of 2 weeks of treatment with feno-
fibrate, renal I/R injury was initiated under anesthesia 
(ketamine 60 mg/kg, i.p. and diazepam 5 mg/kg, i.p.) by 
occlusion of both renal vascular pedicles for 60 minutes, 
followed by 24-hour reperfusion [13].
Serum cholesterol, triglycerides, low-density lipo-
protein (LDL) and high-density lipoprotein (HDL) 
cholesterol levels were measured at the end of the ex-
periment using the semi-automated biochemistry ana-
lyzer-photometer 5010 (Piramal Healthcare, Mumbai, 
India) using a commercially available diagnostic kit 
(Piramal Healthcare).
Estimation of cardiac function
At the end of the experiment, the animals were anesthe-
tized under light ether anesthesia and blood samples 
were collected from the retro-orbital plexuses of each 
rat. The serum was separated and the levels of lactate 
dehydrogenase (LDH) and creatinine kinase (CK) were 
measured by spectrophotometer (UV-1700 dual-beam 
spectrophotometer; Shimadzu Corp., Kyoto, Japan) 
using LDH and CK-MB diagnostic kits (Piramal 
Healthcare).
Estimation of lipid peroxidation and 
protein oxidation
The heart was removed and kept cool on an inverted 
petri dish on ice. It was cross chopped with a surgical 
scalpel into fine slices in chilled 0.25 M sucrose, and 
quickly blotted on a filter paper. The tissue was minced 
and homogenized in 10 mM Tris-HCl buffer, pH 7.4 
(10% w/v), with 25 strokes of a tight Teflon pestle of 
glass homogenizer at a speed of 2,500 rpm. The clear 
supernatant was used for assays of lipid peroxidation 
(malondialdehyde [MDA] content) and protein oxida-
tion (protein carbonyl [PC] content). MDA formation 
was estimated according to the method of Slater and 
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Sawyer [14], and PC content was estimated according 
to the method of Levine et al [15].
Estimation of antioxidant enzymes
The levels of the antioxidant enzymes superoxide 
dismutase (SOD), catalase (CAT) and reduced glu-
tathione (GSH) were estimated. Reduced GSH was 
determined by the method of Moran et al [16]. SOD 
was determined by the method of Misra and Fridovich 
[17]. CAT was estimated by the method of Hugo Aebi 
as given by Colowick et al [18]. Tissue protein was 
estimated using the Biuret method [19] of protein 
assay.
Estimation of xanthine oxidase activity
Tissue xanthine oxidase (XO) activity was measured 
spectrophotometrically by the formation of uric acid 
from xanthine by the increase in absorbance at 293 nm 
[20]. Phosphate buffer (pH 7.5) and xanthine was mixed 
with supernatant sample and then incubated for 30 
minutes at 37°C. The reaction was stopped at 0 and 30 
minutes by the addition of 100% trichloroacetic acid. 
The mixture was then centrifuged at 5,000g for 30 
minutes. The activity was measured at 293 nm. One unit 
of activity was defined as 1 mmol of uric acid formed 
per minute at 37°C, pH 7.5.
Estimation of NO level
NO easily breaks down in the presence of free 
radicals. Hence, nitrite levels were measured as a 
level of NO inactivated due to superoxide radical 
(O2¯). Nitrite was estimated colorimetrically with 
the Griess reagent [21] in homogenate at 540 nm. 
Nitrite was determined from the standard curve ob-
tained using sodium nitrite as standard. The resulting 
equation was used to calculate the unknown sample 
concentrations.
Estimation of myeloperoxidase activity
Myeloperoxidase (MPO) activity was determined using 
a 4-aminoantipyrine/phenol solution as the substrate for 
MPO-mediated oxidation by H2O2. Changes in absor-
bance at 510 nm were recorded [22]. One unit of MPO 
activity is defined as that which degrades 1 μmol H2O2/
min at 25°C.
Statistical analysis
All the values are expressed as mean ± standard error of 
the mean. Statistical significance between more than 
two groups were tested using one-way ANOVA followed 
by the Bonferroni multiple comparisons test using the 
computer-based fitting program GraphPad Prism 5 
(GraphPad Software Inc., San Diego, CA, USA). Dif-
ferences were considered to be statistically significant 
when p < 0.05.
RESULTS
Effect of fenofibrate on lipid profile
Serum cholesterol (p < 0.001), triglyceride (p < 0.001) 
and LDL (p < 0.001) levels were significantly increased 
and HDL (p < 0.05) levels were significantly decreased 
after cholesterol feeding in the HC and HC + I/R groups. 
Fenofibrate treatment significantly reduced elevated 
levels of triglyceride (p < 0.001), cholesterol (p < 0.01) 
and LDL (p < 0.01) in the HC + IR + FF group. But feno-
fibrate did not demonstrate any activity on HDL levels 
(Table 1).
Effect of fenofibrate on cardiac function
LDH and CK levels were significantly increased in both 
I/R and HC + I/R groups (p < 0.001). Fenofibrate treat-
ment significantly reduced elevated levels of LDH 
(p < 0.05) and CK (p < 0.01) in the HC + IR + FF group 
(Table 2).
Effect of fenofibrate on lipid peroxidation and 
protein oxidation
MDA content in the I/R (p < 0.01) and HC + I/R 
(p < 0.001) groups was significantly higher than in the 
normal control (NC) and hyperlipidemic control (HC) 
groups. PC content in the I/R (p < 0.01) and HC + I/R 
(p < 0.001) groups was also significantly higher than 
in the NC and HC groups. Fenofibrate treatment sig-
nificantly reduced elevated MDA (p < 0.05) and 
Table 1. Serum levels of cholesterol, triglyceride, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) in the normal control 
(NC), hyperlipidemic control (HC), ischemia/reperfusion (I/R), HC + I/R, and HC + I/R + fenofibrate (FF) groups*
 Cholesterol (mg/dL) Triglyceride (mg/dL) LDL (mg/dL) HDL (mg/dL)
NC 68.7 ± 7.56 59.8 ± 3.56 26.4 ± 4.63 30.4 ± 2.56
HC 204.5 ± 13.56† 212.4 ± 15.34† 136.3 ± 15.87† 25.7 ± 3.24‡
I/R 73.4 ± 9.56 60.4 ± 16.72 32.4 ± 5.81 28.9 ± 2.78
HC + I/R 215.9 ± 18.44 232.4 ± 23.59 145.9 ± 20.49 23.5 ± 2.57
HC + I/R + FF 150.3 ± 12.45§ 98.5 ± 14.78|| 105.3 ± 10.61§ 25.3 ± 1.98
*Data are presented as mean ± standard error of the mean from 6 animals in each group, and analyzed by one-way ANOVA followed 
by Bonferroni test; †p < 0.001 vs. NC; ‡p < 0.05 vs. NC; §p < 0.01 vs. HC + I/R; ||p < 0.001 vs. HC + I/R.
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PC (p < 0.05) content in the HC + IR + FF group 
(Table 3).
Effect of fenofibrate on antioxidant enzymes
The I/R and HC + I/R groups showed depleted levels of 
the antioxidant enzymes SOD, CAT and GSH when 
compared to the NC and HC groups (p < 0.001). A 
marked restoration in SOD and CAT was observed in 
the HC + I/R + FF group when compared to the HC + IR 
Table 3. Tissue levels of malondialdehyde (MDA) and protein 
carbonyl (PC) in the normal control (NC), hyperlipidemic control 
(HC), ischemia/reperfusion (I/R), HC + I/R, and HC + I/R + fenofi-
brate (FF) groups*
 MDA (nmol/mg protein) PC (nmol/mg protein)
NC 0.54 ± 0.08 0.37 ± 0.05
HC 0.65 ± 0.12 0.50 ± 0.08
I/R 1.23 ± 0.13† 0.86 ± 0.05†
HC + I/R 1.37 ± 0.08‡ 1.29 ± 0.06‡
HC + I/R + FF 0.86 ± 0.09§ 0.92 ± 0.13§
*Data are presented as mean ± standard error of the mean from 
6 animals in each group, and analyzed by one-way ANOVA 
followed by Bonferroni test; †p < 0.01 vs. NC; ‡p < 0.001 vs. HC; 
§p < 0.05 vs. HC + I/R.
group (p < 0.05), but fenofibrate did not have any activ-
ity on GSH level (Table 4).
Effect of fenofibrate on XO activity
XO activity is one of the sources for ROS production, 
and was increased in both the I/R and HC + I/R groups 
when compared to the NC and HC groups (p < 0.001). 
Hyperlipidemia alone (HC group) did not affect XO 
activity. Fenofibrate treatment significantly (p < 0.05) 
reduced elevated XO activity in the HC + IR + FF group 
(Table 4).
Effect of fenofibrate on NO level
NO level was significantly increased in both I/R and 
HC + I/R groups (p < 0.001). Fenofibrate treatment sig-
nificantly (p < 0.01) reduced elevated NO levels in the 
HC + IR + FF group (Table 5).
Effect of fenofibrate on MPO
MPO activity, which is an accepted indicator of neutro-
phil activation, was increased in the I/R and HC + I/R 
groups when compared to the NC and HC groups 
(p < 0.001). Fenofibrate treatment significantly (p < 0.01) 
reduced elevated MPO levels in the HC + IR + FF group 
(Table 5).
Table 4. Tissue levels of superoxide dismutase (SOD), catalase (CAT), reduced glutathione (GSH) and xanthine oxidase (XO) in the normal 
control (NC), hyperlipidemic control (HC), ischemia/reperfusion (I/R), HC + I/R, and HC + I/R + fenofibrate (FF) groups*
 SOD (units/mg protein) CAT (units/mg protein) GSH (nmol/mg protein) XO (units/g protein)
NC 8.5 ± 0.41 6.7 ± 0.50 18.5 ± 1.20 0.64 ± 0.05
HC 6.5 ± 0.74 6.0 ± 0.36 15.97 ± 1.19 0.83 ± 0.09
I/R 5.1 ± 0.40† 3.4 ± 0.27† 10.38 ± 0.50† 1.20 ± 0.07†
HC + I/R 2.7 ± 0.26‡ 1.6 ± 0.14‡ 6.21 ± 0.66‡ 1.56 ± 0.09‡
HC + I/R + FF 5.1 ± 0.36§ 3.4 ± 0.16§ 10.0 ± 0.60 1.18 ± 0.03§
*Data are presented as mean ± standard error of the mean from 6 animals in each group, and analyzed by one-way ANOVA followed 
by Bonferroni test; †p < 0.001 vs. NC; ‡p < 0.001 vs. HC; §p < 0.05 vs. HC + I/R.
Table 5. Tissue levels of myeloperoxidase (MPO) and nitric oxide 
(NO) in the normal control (NC), hyperlipidemic control (HC), 
ischemia/reperfusion (I/R), HC + I/R, and HC + I/R + fenofibrate 
(FF) groups*
 MPO (mU/g protein) NO (μmol/g tissue)
NC 22.18 ± 4.18 0.75 ± 0.06
HC 35.39 ± 4.65 1.23 ± 0.08†
I/R 55.25 ± 2.27‡ 1.52 ± 0.11‡
HC + I/R 81.72 ± 3.76§ 1.98 ± 0.08§
HC + I/R + FF 56.27 ± 5.14|| 1.40 ± 0.11||
*Data are presented as mean ± standard error of the mean from 
6 animals in each group, and analyzed by one-way ANOVA 
followed by Bonferroni test; †p < 0.05 vs. NC; ‡p < 0.001 vs. NC; 
§p < 0.001 vs. HC; ||p < 0.01 vs. HC + I/R.
Table 2. Serum levels of lactate dehydrogenase (LDH) and creatinine 
kinase (CK) in the normal control (NC), hyperlipidemic control 
(HC), ischemia/reperfusion (I/R), HC + I/R, and HC + I/R + fenofi-
brate (FF) groups*
 LDH (U/L) CK (U/L)
NC 1,330 ± 102.9 18.65 ± 1.00
HC 1,820 ± 178.7 26.45 ± 2.37
I/R 2,581 ± 174.8† 38.48 ± 2.33†
HC + I/R 3,487 ± 175.9‡ 49.43 ± 2.72‡
HC + I/R + FF 2,633 ± 167.1§ 35.85 ± 2.43§
*Data are presented as mean ± standard error of the mean from 
6 animals in each group, and analyzed by one-way ANOVA 
followed by Bonferroni test; †p < 0.001 vs. NC; ‡p < 0.001 vs. 
HC; §p < 0.05 vs. HC + I/R.
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DISCUSSION
LDH and CK are important indices of cardiac damage 
in renal failure patients [23,24]. The present study found 
significant increases in the levels of LDH and CK after 
renal I/R in the hyperlipidemic and non-hyperlipidemic 
groups, indicating that changes take place in cardiac 
tissue after renal I/R injury. Fenofibrate treatment pre-
vented alterations in the activity of LDH and CK. These 
results imply that renal I/R causes distant organ injury 
(such as to the heart) and hyperlipidemia can exacerbate 
that injury, but fenofibrate treatment has a protective 
effect against that injury.
In the present study, we found high lipid peroxida-
tion and protein oxidation in cardiac tissue after renal 
I/R injury. The results indicated that there was cardiac 
damage due to renal I/R injury. High MDA and PC 
levels are two major indicators of oxidative stress. The 
question is, what causes this stimulation of distant oxi-
dative stress? An important source of ROS production 
is the inflammatory response. During the process of I/R 
injury, inflammatory reactions are activated, resulting 
in the formation of inflammatory cytokines such as 
tumor necrosis factor (TNF)-α and interleukin (IL)-1 
[25]. Angiotensin II is responsible for proinflammatory 
cytokines and stress. It has been reported that 1–120 
hours after I/R injury, angiotensin II levels are at their 
highest, and maximal tissue damage is observed 12–24 
hours after I/R injury [13]. Thus, we decided to evaluate 
tissue injury after 60 minutes of ischemia and 24 hours 
of reperfusion. The acute inflammatory response is 
characterized by induction of proinflammatory cytoki-
nesis, expression of different adhesion molecules and 
neutrophil infiltration, as well as the production of cy-
tokines such as TNF-α or IL-1. High protein oxidation 
and lipid peroxidation in cardiac tissue has been dem-
onstrated after renal I/R injury [8]. Oxidant injury affects 
cellular molecules including DNA, proteins, and mem-
brane lipids. Demonstration of both protein oxidation 
and lipid peroxidation will aid in a better understanding 
of the exact mechanism by which renal I/R causes car-
diac tissue injury.
Lipid peroxidation and protein oxidation are impor-
tant indicators of oxidant injury. Lipid peroxidation was 
evaluated by measurement of MDA content. Protein 
oxidation was evaluated by measurement of PC content, 
which was increased during oxidative injury [15]. In-
creased production of O2– leads to H2O2, and non-
detoxified H2O2 reacts with Fe++ in a process known as 
the Fenton reaction to produce toxic ROS. Active neu-
trophils show high MPO activity in cardiac tissue, 
which indicates an inflammatory response. In our study, 
cardiac MPO activity was increased in both hyperlipi-
demic and non-hyperlipidemic I/R groups. Kelly found 
increases in immunoreactive IL-1 and TNF-α, and in-
creases in intercellular adhesion molecule-1 mRNA 
levels in the heart after renal I/R injury [6]. Kelly also 
found that there was increased cardiac MPO activity, 
consistent with leukocyte infiltration and activation, in 
the heart [6]. We demonstrated that there was high 
MPO activity in cardiac tissue after renal I/R injury, 
similar to Kelly’s results, which confirm the presence 
of cardiac injury from inflammatory factors due to 
renal I/R.
Neutrophils are major cells involved in ROS produc-
tion, and they play a role in oxidative injury via the 
action of NADPH oxidase or the MPO system. Neutro-
phils produce O2−, which is a ROS. On the other hand, 
hypochlorous acid (HOCl) is produced largely from 
stimulated neutrophils via MPO, which catalyses the 
production of HOCl. HOCl oxidizes cellular molecules 
including proteins, amino acids, carbohydrates, nucleic 
acids, and lipids, increasing cardiac damage [26].
Another radical-producing mechanism might be the 
NO-producing system. The reaction of NO with O2– 
results in peroxynitrite formation, a potent and aggres-
sive cellular oxidant, and causes the formation of 
3-nitro-L-tyrosine [27]. It was found that levels of ni-
trite/nitrate, as the end products of NO conversion, were 
increased in the vascular tissue of hyperlipidemic rats 
compared to non-hyperlipidemic rats [28]. It was re-
ported that hyperlipidemia led to increased activity of 
cardiac inducible NO synthase (iNOS) in high fat diet-
induced hyperlipidemic rats, and NO levels were sig-
nificantly elevated in the hyperlipidemic heart [29]. 
iNOS is involved in the inflammatory process and might 
have a role in the cardiac injury induced by renal I/R 
via activated iNOS-producing cells. Onody et al found 
that there was alteration of ROS production in hyper-
lipidemic cardiac tissue; they used 2% cholesterol 
to induce hyperlipidemia in rats [29]. In this study, we 
used cholesterol 500 mg/kg, p.o.; this dosage did not 
induce lipid peroxidation and protein oxidation, nor did 
it result in any alteration in antioxidant enzyme activity. 
However, we demonstrated that there were elevated 
NO levels in cardiac tissue after renal I/R in the hyper-
lipidemic rats, similar to Onody et al’s cardiac results, 
which confirm the involvement of NO in cardiac dam-
age due to renal I/R in both hyperlipidemic and non-
hyperlipidemic rats.
Patel et al demonstrated that the levels of lipid per-
oxidation and myeloperoxidation, which were increased 
in renal I/R injury, were reduced to within normal ranges 
by fenofibrate. They found high creatinine and urea 
levels in the I/R group compared to the control group 
[10]. Fenofibrate treatment prevented cardiac damage 
induced by renal I/R injury. Our results showed that 
fenofibrate decreased lipid peroxidation and protein 
oxidation in cardiac tissue after renal I/R. Fenofibrate 
serves as a ROS scavenger and is an effective antioxi-
dant. The activity of the antioxidants SOD and CAT in 
cardiac tissue after renal damage was increased after 
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fenofibrate treatment. In addition, fenofibrate prevented 
high MPO activity. Fenofibrate also protected against 
cardiac damage by preventing neutrophil activation 
and ROS production, and by reducing XO activity. 
The observed antioxidant effect of fenofibrate in the 
present study suggests that it may be more related to its 
direct free radical scavenging activity than to its promo-
tion of antioxidant enzyme activity in cardiac tissue. It 
has been previously demonstrated that fenofibrate has 
a preventative effect on brain injury in mice via its direct 
and indirect antioxidant activity [30,31]. Fenofibrate 
scavenges a variety of ROS including hydroxyl radical, 
singlet oxygen and peroxyl radical [32]. Fenofibrate has 
been found to protect tissues against oxidant damage 
induced by I/R [9] and hyperlipidemia [33]. Fenofibrate 
also exerts its effects via an anti-inflammatory mecha-
nism. Kelly found that cardiac TNF-α level was high 
after renal I/R [6]. Fenofibrate prevented cardiac oxida-
tive injury not only by its antioxidant effect but also by 
its anti-inflammatory effect. Fenofibrate decreased the 
high level of NO production and MPO activity in cardiac 
tissue after renal I/R injury. NO is largely produced by 
iNOS during the inflammatory process. Cardiac cells 
are prompted to express an intense level of iNOS activ-
ity once they are exposed to effective stimuli such as 
cytokines [29].
In conclusion, renal I/R injury caused cardiac dam-
age via oxidative stress and inflammatory processes in 
hyperlipidemic and non-hyperlipidemic rats. Our results 
showed that fenofibrate treatment prevented cardiac 
damage induced by renal I/R in hyperlipidemic and 
non-hyperlipidemic rats by decreasing lipid peroxida-
tion and protein oxidation, and increasing antioxidant 
enzyme activity. There may be a significant role of 
proinflammatory mediators during renal I/R to cause 
cardiac injury. The present study confirms the signifi-
cance of oxidative mechanisms in cardiac injury induced 
by renal I/R, both via oxidant markers and prevention 
of this injury with fenofibrate.
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